Threshold of dopamine content and D1 receptor stimulation necessary for the expression of rotational behavior induced by D2 receptor stimulation under normo and supersensitive conditions
We measured the minimum amount of endogenous dopamine (EDA), necessary for the expression of rotational behavior induced by D2 receptor stimulation in striatal or medial forebrain bundle (MFB) lesioned rats. We correlated these results with the minimum dose of D1 receptor agonists needed to substitu...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
1997
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 15121caa a22013697a 4500 | ||
|---|---|---|---|
| 001 | PAPER-20092 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205129.0 | ||
| 008 | 190411s1997 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0031023260 | |
| 024 | 7 | |2 cas |a 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine, 67287-49-4; alpha-Methyltyrosine, 658-48-0; Dopamine, 51-61-6; Methyltyrosines; Quinpirole, 85760-74-3; Receptors, Dopamine D1; Receptors, Dopamine D2 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a NSAPC | ||
| 100 | 1 | |a Dziewczapolski, G. | |
| 245 | 1 | 0 | |a Threshold of dopamine content and D1 receptor stimulation necessary for the expression of rotational behavior induced by D2 receptor stimulation under normo and supersensitive conditions |
| 260 | |c 1997 | ||
| 270 | 1 | 0 | |m Gershanik, O.S.; Inst. Investigac Farmacolog (ININFA), CONICET, Junin 956, 5 Piso (1113) Buenos Aires, Argentina |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Agid, Y., Javoy, F., Glowinski, J., Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat (1973) Nature, 245, pp. 150-151 | ||
| 504 | |a Arnt, J., Behavioural stimulation is induced by separate dopamine D1 and D2 receptor sites in reserpine-pretreated but not in normal rats (1985) Eur J Pharmacol, 113, pp. 79-88 | ||
| 504 | |a Arnt, J., Hyttel, J., Differential inhibition by dopamine D1 and D2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6- hydroxydopamine lesions (1984) Eur J Pharmacol, 102, pp. 349-354 | ||
| 504 | |a Arnt, J., Hyttel, J., Differential involvement of dopamine D1 and D2 receptors in the circling behavior induced by apomorphine, SK and F 38393, pergolide and LY 171555 in 6-OHDA lesioned rats (1985) Psychopharmacology, 85, pp. 346-352 | ||
| 504 | |a Barone, P., Davis, T.A., Braun, A.R., Chase, T.N., Dopaminergic mechanisms and motor function: Characterization of D1 and D2 dopamine receptor interactions (1986) Eur J Pharmacol, 123, pp. 109-114 | ||
| 504 | |a Bédard, P.J., Boucher, R., Effect of D1 stimulation in normal and MPTP monkeys (1989) Neurosci Lett, 104, pp. 223-228 | ||
| 504 | |a Bédard, P.J., Gomez-Mancilla, B., Blanchet, P., Gagnon, C., Dipaolo, T., Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys (1993) Adv Neurol, 60, pp. 113-118 | ||
| 504 | |a Blanchet, P., Bédard, P.J., Britton, D.R., Kebabian, J.W., Differential effect of selective D1 and D2 dopamine receptor agonists on levodopa-induced dyskinesia in MPTP monkeys (1993) J Pharmacol Exp Ther, 267, pp. 275-279 | ||
| 504 | |a Braun, A., Fabbrini, G., Mouradian, M.M., Serrati, C., Barone, P., Chase, T.N., Selective D1 dopamine receptor agonist treatment of Parkinson's disease (1987) J Neural Transm, 68, pp. 41-50 | ||
| 504 | |a Carlson, J.H., Bergstrom, D.A., Walters, J.R., Stimulation of both D1 and D2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: A neurophysiological study (1987) Brain Res, 400, pp. 205-218 | ||
| 504 | |a Carman, L.S., Gage, F.H., Shults, C.W., Partial lesion of the substantia nigra: Relation between extent of lesion and rotational behavior (1991) Brain Res, 553, pp. 275-283 | ||
| 504 | |a Clark, D., White, F.J., D1 dopamine receptor-The search for a function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications (1987) Synapse, 1, pp. 347-388 | ||
| 504 | |a Close, S.P., Marriott, A.S., Pay, S., Failure of SKF 38393-A to relieve parkinsonian symptoms induced by MPTP in the marmoset (1985) Br J Pharmacol, 85, pp. 320-322 | ||
| 504 | |a Colosimo, C., Merello, M., Hughes, A.J., Sieradzan, K., Les, A.J., Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: Implications for the pathogenesis of the on-off phenomenon (1996) J Neurol Neurosurg Psychiatry, 61, pp. 634-637 | ||
| 504 | |a Domino, E.F., Sheng, J., Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys (1993) J Pharmacol Exp Ther, 265, pp. 1387-1391 | ||
| 504 | |a Dravid, A., Jaton, A.L., Enz, A., Frei, P., Spontaneous recovery from motor asymmetry in adult rats with 6-hydroxydopamine-induced partial lesions of the substantia nigra (1984) Brain Res, 311, pp. 361-365 | ||
| 504 | |a Gershanik, O., Heikkila, R.E., Duvoisin, R.C., Effects of dopamine depletion on rotational behavior to dopamine agonists (1983) Brain Res, 261, pp. 358-360 | ||
| 504 | |a Goldstein, M., Lieberman, A., Meller, E., A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa (1985) Trends Pharmacol Sci, 6, pp. 436-437 | ||
| 504 | |a Goldstein, M., Lieberman, A., Meller, E., Goldstein et al. reply (1986) Trends Pharmacol Sci, 7, pp. 225-228 | ||
| 504 | |a Gómez-Mancilla, B., Bédard, P.J., Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine trated monkeys (1991) J Pharmacol Exp Ther, 259, pp. 409-413 | ||
| 504 | |a Hefti, F., Melamed, E., Wurtman, R.J., Partial lesions of the dopaminergic nigrostriatal system in rat brain: Biochemical characterization (1980) Brain Res, 195, pp. 123-137 | ||
| 504 | |a Jackson, D.M., Hashizume, M., Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D1 receptors (1987) J Neural Transm, 69, pp. 131-145 | ||
| 504 | |a Kebabian, J.W., Britton, D.R., Deninno, M.P., Perner, R., Smith, L., Jenner, P., Schoenleber, R., Williams, M., A-77636: A potent selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets (1992) Eur J Pharmacol, 229, pp. 203-209 | ||
| 504 | |a König, J.F.R., Klippel, R.A., (1963) The Rat Brain. A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem, , Williams & Wilkins, New York | ||
| 504 | |a Luquin, M.R., Lagerna, J., Herrero, T., Obeso, J.A., CY-208243 anti-parkinsonian effect in MPTP-treated monkeys is mediated by D1 receptor activation (1990) Mov Disorders, 5, p. 78 | ||
| 504 | |a Luquin, M.R., Guillen, J., Martinez-Vila, E., Laguna, J., Martinez-Lage, J.M., Functional interaction between dopamine D1 and D2 receptors in "MPTP" monkeys (1994) Eur J Pharmacol, 253, pp. 215-224 | ||
| 504 | |a Mashurano, M., Waddington, J.R., Stereotyped behaviour in response to the selective D2 dopamine receptor agonist Ru 24213 is enhanced by treatment with the selective D1 agonist SKF 38393 (1986) Neuropharmacology, 25, pp. 947-949 | ||
| 504 | |a Nomoto, M., Jenner, P., Marsden, C.D., The dopamine D2 agonist LY-131865 but not the D1 agonist SKF 38393 reverses parkinsonism induced by 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset (1985) Neurosci Lett, 57, pp. 37-44 | ||
| 504 | |a Robertson, G.S., Robertson, H.A., Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats (1986) Brain Res, 384, pp. 387-390 | ||
| 504 | |a Robertson, H.A., Robertson, G.S., The antiparkinson action of bromocriptine in combination with levodopa (1986) Trends Pharmacol Sci, 7, pp. 224-227 | ||
| 504 | |a Robertson, H.A., Robertson, G.S., Combined L-Dopa and bromocriptine therapy for Parkinson's disease: A proposed mechanism of action (1987) Clin Neuropharmacol, 10, pp. 384-387 | ||
| 504 | |a Schwarcz, R., Fuxe, K., Agnati, L.F., Hökfelt, T., Coyle, J.T., Rotational behaviour in rats with unilateral striatal kainic acid lesions: A behavioural model for studies on intact dopamine receptors (1979) Brain Res, 170, pp. 485-495 | ||
| 504 | |a Schwartz, J.C., Giros, B., Martres, M.P., Sokoloff, P., The dopamine receptor family: Molecular biology and pharmacology (1992) Semin Neurosci, 4, pp. 99-108 | ||
| 504 | |a Shiosaki, K., Jenner, P., Asin, K.E., ABT-431: The diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease (1996) J Pharmacol Exp Ther, 276, pp. 150-160 | ||
| 504 | |a Sonsalla, P.K., Manzino, L., Heikkila, R.E., Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway (1988) J Pharmacol Exp Ther, 247, pp. 180-185 | ||
| 504 | |a Taylor, J.R., Lawrence, M.S., Redmond Jr., D.E., Elsworth, J.D., Roth, R.H., De Nichols, Mailman, R.B., Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys (1991) Eur J Pharmacol, 199, pp. 389-391 | ||
| 504 | |a Telmet, J.A., Chang, P.N., Oertel, W.H., Jenner, P., Marsden, C.D., The D1 dopamine receptor partial agonist CY-208243 exhibit antiparkinsonian activity in the MPTP-treated marmoset (1988) Eur J Pharmacol, 156, p. 197 | ||
| 504 | |a Ungerstedt, U., Arbuthnott, G.W., Quantitative recording of rotational behavior in rats after 6-OHDA lesions of the nigrostriatal dopamine system (1970) Brain Res, 24, pp. 485-493 | ||
| 504 | |a Waddington, J.L., Bromocriptine, selective D2 dopamine receptor agonists and D1 dopaminergic tone (1986) Trends Pharmacol Sci, 7, pp. 223-224 | ||
| 504 | |a Waddington, J.L., O'Boyle, K.M., The D1 dopamine receptor and the search for its functional role: From neurochemistry to behaviour (1987) Rev Neurosci, 1, pp. 157-184 | ||
| 504 | |a Waddington, J.L., Daly, S.A., McCauley, P.G., O'Boyle, K.M., Levels of functional interaction between D1-like and D2-like dopamine receptor systems (1994) Dopamine Receptors, pp. 511-537. , Niznik HB (eds) Marcel Dekker, New York | ||
| 504 | |a Waddington, J.L., Daly, S.A., Downes, R.P., Deveney, A.M., McCauley, P.G., O'Boyle, K.M., Behavioural pharmacology of 'D1-like' dopamine receptors: Further subtyping, new pharmacological probes and interactions with 'D2-like' receptors (1995) Prog Neuro-Psychopharmacol Biol Psychiatry, 19, pp. 811-831 | ||
| 504 | |a Walters, J.R., Bergstrom, D.A., Carlson, J.H., Chase, T.N., Braun, A.R., D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects (1987) Science, 236, pp. 719-722 | ||
| 504 | |a Watts, V.J., Lawler, C.P., Gilmore, J.H., Southerland, S.B., Nichols, D.E., Mailman, R.B., Dopamine D1 receptors: Efficacy of full (dihydrexidine) vs partial (SKF-38393) agonists in primates vs rodents (1993) Eur J Pharmacol, 242, pp. 165-172 | ||
| 504 | |a Weick, B.G., Walters, J.R., Effects of D1 and D2 dopamine receptors stimulation on the activity of substantia nigra pars compacta neurons in 6-OHDA lesioned rats: D1/D2 coactivation induces potentiated responses (1987) Brain Res, 405, pp. 234-246 | ||
| 520 | 3 | |a We measured the minimum amount of endogenous dopamine (EDA), necessary for the expression of rotational behavior induced by D2 receptor stimulation in striatal or medial forebrain bundle (MFB) lesioned rats. We correlated these results with the minimum dose of D1 receptor agonists needed to substitute EDA in its permissive role for D2 motor effects to take place. Rats with unilateral quinolinic acid (QA) striatal or 6-hydroxydopamine (6-OHDA) MFB lesions were given increasing doses of the tyrosine hydroxylase inhibitor alpha-methyl-para-tyrosine (AMPT) in combination with a fixed dose of the D2 receptor agonist quinpirole (trans-(-)-4aR-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1 H-pyrazolo(3,4-g)quinoline hydrochloride) and tested for rotational behavior. The animals were later sacrificed and striata removed; EDA was measured by high performance liquid chromatography (HPLC). Rotational responses were abolished by increasing doses of AMPT inducing a stepwise depletion of EDA. EDA content and rotational behavior to D2 stimulation showed a high degree of correlation. There was an abrupt reduction in rotational behavior at dopamine levels of 50-60% of controls in both animal models. In addition, striatal or MFB lesioned rats which were maximally depleted of dopamine by AMPT pretreatment received a fixed dose of quinpirole and then challenged with increasing doses of a D1 receptor agonist SKF 38393 ((±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine- 7,8-diol hydrochloride). Rotational behavior was restored by SKF 38393 in both animal models in a dose-dependent fashion. Our results confirm the need for simultaneous D1/D2 stimulation in the generation of rotational behavior in both animal models. Moreover, they demonstrate the existence of a threshold level of D1 stimulation necessary to exert its permissive role on D2 mediated responses. |l eng | |
| 593 | |a Inst. de Invest. Farmacologicas, CONICET, Junin 956, (1113) Buenos Aires, Argentina | ||
| 593 | |a Inst. de Ing. Genet. y Biol. Molec., UBA-CONICET, Obligado 2490, (1428) Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a CIRCLING BEHAVIOR |
| 690 | 1 | 0 | |a DOPAMINE AGONISTS |
| 690 | 1 | 0 | |a DOPAMINE RECEPTORS |
| 690 | 1 | 0 | |a ENDOGENOUS DOPAMINE |
| 690 | 1 | 0 | |a RAT |
| 690 | 1 | 0 | |a 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE |
| 690 | 1 | 0 | |a APOMORPHINE |
| 690 | 1 | 0 | |a DESIPRAMINE |
| 690 | 1 | 0 | |a DOPAMINE |
| 690 | 1 | 0 | |a DOPAMINE 2 RECEPTOR |
| 690 | 1 | 0 | |a DOPAMINE RECEPTOR STIMULATING AGENT |
| 690 | 1 | 0 | |a METIROSINE |
| 690 | 1 | 0 | |a PERGOLIDE MESILATE |
| 690 | 1 | 0 | |a QUINOLINIC ACID |
| 690 | 1 | 0 | |a QUINPIROLE |
| 690 | 1 | 0 | |a ANIMAL EXPERIMENT |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CIRCLING BEHAVIOR |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DOSE RESPONSE |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a INTRAPERITONEAL DRUG ADMINISTRATION |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a RAT |
| 690 | 1 | 0 | |a SUBCUTANEOUS DRUG ADMINISTRATION |
| 690 | 1 | 0 | |a 2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE |
| 690 | 1 | 0 | |a ALPHA-METHYLTYROSINE |
| 690 | 1 | 0 | |a ANIMALS |
| 690 | 1 | 0 | |a BEHAVIOR, ANIMAL |
| 690 | 1 | 0 | |a DOPAMINE |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a METHYLTYROSINES |
| 690 | 1 | 0 | |a QUINPIROLE |
| 690 | 1 | 0 | |a RATS |
| 690 | 1 | 0 | |a RATS, WISTAR |
| 690 | 1 | 0 | |a RECEPTORS, DOPAMINE D1 |
| 690 | 1 | 0 | |a RECEPTORS, DOPAMINE D2 |
| 690 | 1 | 0 | |a ROTATION |
| 653 | 0 | 0 | |a skf 38393, rbi, United States |
| 700 | 1 | |a Mora, M.A. | |
| 700 | 1 | |a Menalled, L.B. | |
| 700 | 1 | |a Stéfano, F.J.E. | |
| 700 | 1 | |a Rubinstein, M. | |
| 700 | 1 | |a Gershanik, O.S. | |
| 773 | 0 | |d 1997 |g v. 355 |h pp. 30-35 |k n. 1 |p NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL. |x 00281298 |t Naunyn-Schmiedeberg's Archives of Pharmacology | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031023260&doi=10.1007%2fPL00004914&partnerID=40&md5=cd38ccf308158f2aefaf5356a97efe5a |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1007/PL00004914 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_00281298_v355_n1_p30_Dziewczapolski |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00281298_v355_n1_p30_Dziewczapolski |y Registro en la Biblioteca Digital |
| 961 | |a paper_00281298_v355_n1_p30_Dziewczapolski |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||